SUBSCRIBE
SUBSCRIBE
News   Drug Development

Valeant Pharmaceuticals International May Fall if New Drug Disappoints-Barron’s

November 23, 2009 | 
1 min read
Bookmark and Share

Reuters -- Investors could shave off a third of the valuation of Valeant Pharmaceuticals International (VRX.N) if its prospective epilepsy drug retigabine fails to live up to expectations, according to a Barron's report.
Clinical research Phase 2
Valeant Pharmaceuticals International
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Drug pricing
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
February 24, 2026
 · 
3 min read
 · 
Jef Akst
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
 · 
4 min read
 · 
Annalee Armstrong